Vasculopathy Augments Cardiovascular Risk in Community-Dwelling Elderly with Left Ventricular Hypertrophy

Rusitanmujiang Maimaitiaili1, Song Zhao1, Jiadela Teliewubai1

  • 1Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Middle Yanchang Road, Shanghai 200072, China.

Insights

Left ventricular hypertrophy (LVH) significantly increases cardiovascular risk in older adults, especially when combined with multiple vasculopathies. Renal senescence is also an independent risk factor for major adverse cardiovascular events (MACEs).

Area of Science:

  • Cardiology
  • Gerontology
  • Vascular Medicine

Background:

  • Left ventricular hypertrophy (LVH) is a common cardiac adaptation in the elderly.
  • The interplay between LVH, various vasculopathies, and cardiovascular risk requires further investigation.

Purpose of the Study:

  • To assess the combined impact of different left ventricular (LV) geometries and vasculopathies on major adverse cardiovascular events (MACEs) in an elderly cohort.
  • To identify independent risk factors for MACEs in older adults.

Main Methods:

  • Prospective cohort study of 3339 older adults (Northern Shanghai Study).
  • Classification of LV geometry into normal, concentric remodeling, eccentric hypertrophy, and concentric hypertrophy using echocardiography.
  • Categorization of vasculopathy into arteriosclerosis, atherosclerosis, and renal senescence.
  • Follow-up for a median of 5.7 years to identify MACEs (myocardial infarction, stroke, cardiovascular death).
  • Statistical analysis using Cox regression and Kaplan-Meier survival analysis.

Main Results:

  • Concentric hypertrophy was associated with higher hypertension prevalence, increased vascular stiffness, and the highest MACE rate.
  • Eccentric hypertrophy (HR: 1.638) and concentric hypertrophy (HR: 1.751) significantly increased MACE risk.
  • Renal senescence independently elevated MACE risk (HR: 1.361).
  • Concomitant LVH and multiple vasculopathies led to the most significant reduction in survival probability.
  • LVH amplified MACE risk in older males with hypertension, diabetes, or vasculopathy.

Conclusions:

  • LVH is a critical predictor of adverse cardiovascular outcomes in the elderly.
  • The presence of multiple vasculopathies compounds cardiovascular risk in individuals with LVH.
  • Renal senescence emerges as a distinct, independent risk factor for MACEs, warranting clinical attention.

Related Concept Videos

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
503
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
168